Overview
- Albertsons, which reported results Tuesday, posted a $480.8 million Q4 net loss after recording a $773.8 million opioid settlement charge to be paid over nine years without admitting wrongdoing.
- Same‑store sales rose 0.7% in Q4 as pharmacy weighed on results by about 145 basis points from Inflation Reduction Act pricing changes and slower growth in GLP‑1 weight‑loss and diabetes drugs.
- Quarterly revenue increased 7.7% to $20.25 billion, including about $1.4 billion from an extra week in the quarter, and adjusted EBITDA was $903 million.
- For fiscal 2026, guidance calls for 0% to 1% identical sales and $3.85 billion to $3.93 billion in adjusted EBITDA, with a roughly 150‑basis‑point IRA headwind and planned capital spending of $2.0 billion to $2.2 billion.
- Albertsons raised its quarterly dividend 13% to 17 cents and expanded its share repurchase authorization to $2 billion as it balances pharmacy headwinds with returns to shareholders.